Here, we utilize newly described syngeneic MOC models of murine oral cavity cancer [20] to demonstrate differential effects of the mTOR inhibitor rapamycin and the MEK1/2 inhibitor PD901 alone or in combination on oncogenic signaling, tumor responses and survival and immune modulation in highly immunogenic (MOC1) and poorly immunogenic (MOC2) tumors. Here, MTOR is linked to oral cavity cancer.